Malaria in Africa: why most countries haven’t beaten it yet
WHO acknowledged these factors when it excluded Africa from its first Global Malaria Eradication Campaign, which ran from 1955 until 1969.
Nigeria’s universities can find funds and produce job creators: here’s how
Industrial action by Nigeria’s university lecturers has entered its seventh month. The strike is one of the longest by academic staff in Africa’s most populous country.
Top 25 Most Powerful Women in the C-Suite Impacting Business 2022
Since Rebecca Miano’s appointment to the helm of KenGen in 2017, the seasoned corporate lawyer has proven her prowess as a corporate strategist and savvy business leader.
Top 25 Most Powerful Women in the C-Suite Impacting Business 2022
According to Rebecca Mbithi, Family Bank continues to provide innovative products and superior customer experience which has witnessed Family Bank customers recognize the bank as the best bank in customer responsiveness and digital experience in 2022
Debt distress in Africa: biggest problems, and ways forward
The ability of countries to manage their debt is complicated by the changing composition of the debt.
Antibiotic use in Uganda is high: Action is needed
Covid-19 is caused by a virus. And viruses are not treated with antibiotics.
Making Covid vaccines in Africa: Advances and sustainability issues
African countries failed to secure the vaccines they needed. As a result, pressure began to mount on the leaders of African countries to develop local Covid vaccine manufacturing capacity.
Top 25 Most Transformative Corporate Brands Impacting Business 2022
Microsoft has in recent years significantly expanded its focus in Kenya beyond operating systems.
Wins, missteps and lessons: African experts reflect on two years of Covid response
The fact that two years into the pandemic, the North-South disparities and unequal power structures in global health are still intact is a huge cause for concern
How drug companies are sidestepping the WHO’s technology transfer hub in Africa
Moderna’s decision to continue making the vaccine itself, though on the Kenyan site, is a signal that the company (at least for the moment) is not considering licensing its technology to a third party for local manufacture.